{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-012335","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.702204+00:00","generated_at":"2026-06-04T04:45:28.902758+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"bioAffinity Technologies reports FY2023 revenue of $2.5M, up from $5K; CyPath Lung orders grow 350% in Q1 2024","bullets":["FY2023 revenue $2.5M vs $5K in 2022; net loss $7.9M ($0.91/sh) vs $8.1M ($1.81/sh).","Q4 2023 revenue $2.2M vs nil prior year; net loss $2.4M vs $1.7M.","Cash and equivalents $2.8M at Dec 31, 2023.","CMS final payment determination for CyPath Lung for 2024; CyPath Lung orders up 350% in Q1 2024 vs Q4 2023.","Appointed Michael Dougherty as CFO; Dallas Coleman as National Director of Sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-012335","json":"https://secwatch.observer/filing/0001493152-24-012335.json","markdown":"https://secwatch.observer/filing/0001493152-24-012335.md","text":"https://secwatch.observer/filing/0001493152-24-012335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/0001493152-24-012335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:45:28.902758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1301e659ab77453e797d1c3a35f15c2c8ef7431","claim":"bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2023 results: revenue $2.5 million, net income $7.9 million, EPS $0.91 per share.","evidence_excerpt":"expanding our market to fulfill the promise of early cancer detection and treatment.” Fourth Quarter Financial Results Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period. Revenue was derived from sales and services of the Company’s commercial laboratory, Precision Pathology Laboratory Services,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/0001493152-24-012335-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and 12 months ended December 31, 2023"},{"label":"Revenue","value":"$2.5 million"},{"label":"Net income","value":"$7.9 million"},{"label":"EPS","value":"$0.91 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c1301e659ab77453e797d1c3a35f15c2c8ef7431","claim":"bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2023 results: revenue $2.5 million, net income $7.9 million, EPS $0.91 per share.","evidence_excerpt":"today reported financial results for the three and 12 months ended December 31, 2023. Fiscal Year 2023 and Recent Highlights ● Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath ® Lung,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/0001493152-24-012335-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and 12 months ended December 31, 2023"},{"label":"Revenue","value":"$2.5 million"},{"label":"Net income","value":"$7.9 million"},{"label":"EPS","value":"$0.91 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}